Pasithea Therapeutics (KTTA) Treasury Shares (2021 - 2023)

Pasithea Therapeutics (KTTA) posted Treasury Shares of $20.8 million for Q3 2023, up 671.11% sequentially from $2.7 million in Q4 2022.

Pasithea Therapeutics (KTTA) Treasury Shares (2021 - 2023) Analysis & Trends

Pasithea Therapeutics has reported Treasury Shares for 3 years, with the latest figure at $20.8 million in Q3 2023.

Quarterly Treasury Shares changed N/A year-over-year to $20.8 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $20.8 million (changed N/A YoY) and the FY2022 annual result came in at $2.7 million, up 26900.0% from the prior year.
Treasury Shares rose to $20.8 million in Q3 2023 per KTTA's latest filing, from $2.7 million in the prior quarter.
Over five years, Treasury Shares peaked at $20.8 million in Q3 2023 and troughed at $10000.0 in Q4 2021.
A 3-year average of $7.8 million and a median of $2.7 million in 2022 frame the typical range for Treasury Shares.
The widest YoY moves for Treasury Shares: up 26900.0% in 2022, down 26900.0% in 2022.
Over 3 years, Treasury Shares stood at $10000.0 in 2021, then surged by 26900.0% to $2.7 million in 2022, then surged by 671.11% to $20.8 million in 2023.
According to Business Quant data, Treasury Shares over the past three periods registered $20.8 million, $2.7 million, and $10000.0 for Q3 2023, Q4 2022, and Q4 2021 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	2.72 Mn
10	Pasithea Therapeutics	16.97 Mn	16.97 Mn	-	-

Download Data